Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.9 (2.65%)
Data as of 02/23/18 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $33.00 with a 52 week high of $41.80 and a 52 week low of $13.90.
Recent NewsMore >>
Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Andrew H. Chang
Director, Investor Relations
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.